Rituximab and non-pegylated liposomial doxorubicin (R-NPLD) treatment in patients 80 years of age or older affected by diffuse large B-cell lymphoma (DLBCL): A 2020 update and implications of clinical and pathological factors

Data presented during the 2021 European Society for Medical Oncology Congress demonstrated the efficacy and safety of rituximab plus nonpegylated liposomal doxorubicin in patients age 80 years or older with untreated CD20-positive DLBCL. Among the 50 patients included in the study, the 3-year overall, cause-specific, and disease-free survival rates were 49.9% ± 7.6%, 55.5% ± 7.9%, and 48.5% ± 7.8%, respectively. Three-year overall survival among patients who reached event-free status at 12 months and 18 months was 66% ± 13.0% and 67.9% ± 7.0%, respectively.